Traditionally, medication is delivered to the eye by three main mechanisms: Topical ocular administration, systemic administration, and intraocular or periocular injection. Each of these methods has significant disadvantages. Topical ocular solutions or ointments have less than a 1% penetration, have rapid dilution and tear washout, and rely substantially on owner compliance to administer the m...

Biopharmaceuticals are making increasing impact on medicine, including treatment of indications in the eye. Macromolecular drugs are typically given by physician-administered invasive delivery methods, because non-invasive ocular delivery methods, such as eye drops, and systemic delivery, have low bioavailability and/or poor ocular targeting. There is a need to improve delivery of biopharmaceut...

Normal vision depends on the optimal function of ocular barriers and intact membranes that selectively regulate the environment of ocular tissues. Novel pharmacotherapeutic modalities have aimed to overcome such biological barriers which impede efficient ocular drug delivery. To determine the impact of ocular barriers on research related to ophthalmic drug delivery and targeting, herein we prov...

Delivery of drugs into eyes using conventional drug delivery systems, such as solutions, is a considerable challenge to the treatment of ocular diseases. Drug loss from the ocular surface by lachrymal fluid secretion, lachrymal fluid-eye barriers, and blood-ocular barriers are main obstacles. A number of ophthalmic drug delivery carriers have been made to improve the bioavailability and to prol...

In developing a drug delivery strategy, issues of absorption, distribution, metabolism, and elimination must be considered. The eye presents unique opportunities and challenges when it comes to the delivery of pharmaceuticals. While absorption by this route is bungling, there are few side effects with conventional ocular dosage forms. Hence, ocular inserts were prepared with prolonged release o...

Despite numerous scientific efforts many challenges need to be overcome in the ocular delivery because eyes have special and complex anatomic structures. The main problem with the conventional dosage forms is poor ocular bioavailability due to minimum ocular residence time, because of various anatomical and pathophysiological barriers prevailing in the eye. For this reason, much effort has been...

Ocular drug delivery is challenging field to pharmaceutical scientists owing to the underlying anatomical, physiological and dynamic constraints put forth by the eye. Nonetheless, there is increasing need to overcome these barriers for the treatment of sight threatening ophthalmic ailments. Novel drug delivery strategies are being explored while intravitreal injections are still a standard trea...

Over the recent decades, there has been seismic shift in the field of ocular drug delivery ranging from dosage form design to drug product commercialization. Advancements in the fields of nanotechnology, biomedical engineering and clinical science significantly improved the feasibility of ocular drug delivery. Despite these technological advances, there exists need to deliver drugs in therapeut...